Results 111 to 120 of about 8,676,773 (167)

A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia. [PDF]

J Clin Sleep Med
Bogan RK, Fuller DS, Whalen M, Casstevens C, Schneider LD.   +4 more
europepmc   +1 more source

Sleep disorders in Parkinson's disease: evaluating pharmacological treatments through systematic review and meta-analysis. [PDF]

BMC Neurol
Li J, Zhou R, Deng J, Zhou H, Hu J, Wang X.   +5 more
europepmc   +1 more source

The Mechanisms of Magnesium in Sleep Disorders. [PDF]

Nat Sci Sleep
He C, Wang B, Chen X, Xu J, Yang Y, Yuan M.   +5 more
europepmc   +1 more source

Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice [PDF]

Sleep Medicine, 2017
Background Sodium oxybate is licensed in Europe for the treatment of narcolepsy with cataplexy in adults. The aim of this study was to assess the efficacy and safety of sodium oxybate in clinical practice in patients with narcolepsy and cataplexy ...
Brian Kent, Guy Leschziner, Joerg Sebastian Steier   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

0647 Efficacy of Low-Sodium Oxybate in Narcolepsy Patients with and Without Cardiovascular or Cardiometabolic Disorders

SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy, and idiopathic hypersomnia in adults.
Bruce Corser, Shawn Candler, Wayne Macfadden, Douglas Fuller, Thomas Measey, Richard Bogan   +5 more
openaire   +1 more source

1012 Individualized Dosing with Low-Sodium Oxybate in Narcolepsy: Patient Voices from LYRICAL

SLEEPJ
Abstract Introduction In the US, low-sodium oxybate (LXB; Xywav®) is approved for treating cataplexy or excessive daytime sleepiness (EDS) in patients aged ≥7 years with narcolepsy and has the option for individualized dosing.
Caroleen Drachenberg, Meagan Farrell, Jennifer D’Souza, Emily Kim, Meaghan Lawrence, Christina Graham, Marisa Whalen, Jessica Alexander, Silky Beaty, Sarah Markt, Laura Herpel   +10 more
openaire   +1 more source

0862 Sleep Architecture with Low-Sodium Oxybate Treatment in Narcolepsy: Results from the DUET Study

SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Chad Ruoff, Logan Schneider, R Sangal, Deborah Nichols, Teresa Steininger, Douglas Fuller, M Kirby, Jessica Alexander, Emmanuel Mignot   +8 more
openaire   +1 more source

0831 Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Results from the DUET Study

SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) assessing the effectiveness of low-sodium oxybate (LXB; Xywav®) treatment on daytime and ...
Logan Schneider, Chad Ruoff, David Plante, Deborah Nichols, Teresa Steininger, Douglas Fuller, M Kirby, Sarah Akerman, Jessica Alexander, Marisa Whalen, Alyssa Cairns   +10 more
openaire   +1 more source

0633 Efficacy and Safety of Low-Sodium Oxybate in Narcolepsy Patients With/Without Psychiatric/Neurologic Comorbidities

SLEEP
Abstract Introduction Prior studies report high incidences of psychiatric and/or neurologic comorbidities in patients with narcolepsy. Low-sodium oxybate (LXB; Xywav®) is an FDA-approved treatment for cataplexy or excessive daytime sleepiness in patients ≥7 years old with narcolepsy and for adults ...
Craig Chepke, Andrew Cutler, Nathaniel Watson, Shawn Candler, Douglas Fuller, Thomas Measey, Brian Scheckner, Sarah Akerman, Wayne Macfadden   +8 more
openaire   +1 more source